Serum COMP and MMP-3 in Knee Osteoarthritis

ConditionKnee Osteoarthritis

Trial statusNot yet recruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age40-75

SponsorKanuni Sultan Suleyman Training and Research Hospital

About this trial

Knee osteoarthritis is a common degenerative joint disease characterized by pain, stiffness, and functional limitation, significantly affecting quality of life. In addition to mechanical factors, cartilage degradation and extracellular matrix remodeling play a key role in disease progression. Therefore, identifying reliable biomarkers reflecting disease severity has become an important research focus.

Cartilage oligomeric matrix protein (COMP) is a structural component of cartilage associated with cartilage turnover, while matrix metalloproteinase-3 (MMP-3) is a proteolytic enzyme involved in extracellular matrix degradation. Both biomarkers have been suggested to be elevated in osteoarthritis and may reflect disease severity.

The aim of this cross-sectional observational study is to evaluate the relationship between serum COMP and MMP-3 levels and clinical and radiological severity in patients with knee osteoarthritis. Pain severity will be assessed using the Visual Analog Scale (VAS), functional status with the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and radiological severity with the Kellgren-Lawrence classification. Functional performance will also be evaluated using the 5 Times Sit-to-Stand Test.

Additionally, serum COMP and MMP-3 levels will be compared between patients with knee osteoarthritis and healthy controls. The findings of this study are expected to contribute to a better understanding of the relationship between biochemical markers and clinical severity in osteoarthritis and may provide insight into their potential diagnostic and prognostic value.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Age between 40 and 75 years Male and female participants For patient group: clinically and radiologically confirmed diagnosis of knee osteoarthritis Kellgren-Lawrence grade 2-3 (or 2-4 if you decide to include advanced stages) Ability to understand and comply with study procedures Willingness to participate and provision of written informed consent For control group: absence of knee pain and no radiographic evidence of knee osteoarthritis

Disqualifiers

Presence of inflammatory rheumatic diseases (e.g., rheumatoid arthritis, ankylosing spondylitis) History of acute knee trauma Previous knee surgery (e.g., arthroplasty or arthroscopy) History of septic arthritis or active infection History of malignancy Severe systemic diseases (e.g., advanced cardiac, renal, or hepatic failure) Neuromuscular disorders affecting lower extremity function Intra-articular injection (e.g., corticosteroids, PRP) within the last 3 months Other conditions that may cause knee pain apart from osteoarthritis Cognitive or psychiatric conditions preventing compliance with study procedures Refusal to provide informed consent

Trial population

The study population will consist of adult participants aged 40-75 years recruited from the outpatient clinic of Physical Medicine and Rehabilitation. The patient group will include individuals with clinically and radiologically confirmed knee osteoarthritis, while the control group will consist of age- and sex-matched healthy volunteers without knee pain or radiographic evidence of osteoarthritis. All participants will be able to comply with study procedures and will provide written informed consent prior to enrollment.

Trial design

Design model

Case-control

Time perspective

Cross-sectional

Treatments tested in this trial

Observational Study
Other intervention
This is an observational study with no intervention. Participants will undergo clinical, radiological, and laboratory assessments, including serum biomarker analysis, without any therapeutic or experimental intervention.

Treatment groups

60 Participants

are divided into 2 treatment groups

Group A: Knee Osteoarthritis1 intervention

Group B: Healthy Control1 intervention

Trial outcomes

Primary outcomes

Serum COMP and MMP-3 Levels

Serum levels of cartilage oligomeric matrix protein (COMP) and matrix metalloproteinase-3 (MMP-3) will be measured using ELISA. The association between biomarker levels and clinical (VAS, WOMAC), functional (5 Times Sit-to-Stand Test), and radiological (Kellgren-Lawrence grade) severity parameters will be evaluated.

Time frame

At baseline

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Kanuni Sultan Suleyman Training and Research Hospital

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: